問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Psychiatry

更新時間：2023-09-19

簡意玲CHIEN, YI-LING
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 1 個月

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

簡意玲

List

14Cases

2020-10-15 - 2022-06-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2021-04-26 - 2024-07-22

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2020-12-01 - 2025-08-31

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2021-10-01 - 2025-04-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting5Sites

Terminated5Sites

2021-04-01 - 2024-12-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting6Sites

Terminated4Sites

2019-07-15 - 2020-12-31

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Terminated2Sites

2022-01-01 - 2024-04-09

Phase II

A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part II

  • Condition/Disease

    Attention-Deficit Hyperactivity Disorder (ADHD)

  • Test Drug

    PDC-1421 Capsule

Participate Sites
5Sites

Recruiting5Sites

2014-10-09 - 2018-12-31

Phase III

Confirmatory Study of DSP-5423P in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    Schizophrenia

  • Test Drug

    DSP-5423P

Participate Sites
6Sites

Terminated6Sites

黃宗正
National Taiwan University Hospital

2010-09-01 - 2012-12-31

Phase III

A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in subjects with an acute exacerbation of schizophrenia (Phase 3 ; Protocol No. P06124)

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Asenapine (SCH 900274)

Participate Sites
13Sites

Terminated13Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2021-02-01 - 2023-09-05

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB